Abstract: The present invention is a device for aligning a user's pelvis. The device may have a first end with a first end leg cup and a first end strap. A second end may be configured opposite the first end. The second end may have a second end leg cup and second end strap. A bridge may connect the first end and second end. The device may be placed between a user's legs whereby one of the user's legs is configured at least partially within the first end leg cup and the other of the user's legs is configured at least partially within the second leg cup. The user's legs may be secured to the device by the first end strap and second end strap. The user may perform a series of abductions and adductions whereby the device provides resistance to the user which aids in aligning the user's pelvis.

Abstract: An exercise ball having a transparent water level indicating system is disclosed. The exercise ball has a liquid impermeable shell which creates an interior chamber and forms a covering surface for the exercise ball. The interior chamber is filled with a fluid such as water through a valve provided on the liquid impermeable shell. The valve includes an air tight closure which prevents the leakage of the fluid during exercise. A transparent portion provided on the liquid impermeable shell of the exercise ball indicates a level of the fluid filled within the interior chamber. The transparent portion includes a plurality of markings for providing direct indication of a weight of the exercise ball. A user can directly view the level of the fluid filled in the exercise ball and thereby can read a present weight of the exercise ball with the fluid.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.